An update on the current and emerging targeted agents in metastatic colorectal cancer.
about
Current targeted therapies in the treatment of advanced colorectal cancer: a reviewRecent insights into nanotechnology development for detection and treatment of colorectal cancerHER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutationMaintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial.Secular trends in colon and rectal cancer relative survival.Protein kinase d as a potential chemotherapeutic target for colorectal cancer.Patients' preferences for participation in treatment decision-making at the end of life: qualitative interviews with advanced cancer patients.Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis.Colorectal cancer with liver metastases: neoadjuvant chemotherapy, surgical resection first or palliation alone?Aflibercept in the treatment of metastatic colorectal cancer.Ziv-aflibercept in metastatic colorectal cancerSelective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX sPien Tze Huang Inhibits Hypoxia-Induced Angiogenesis via HIF-1 α /VEGF-A Pathway in Colorectal Cancer.Targeting cytosolic phospholipase A2 α in colorectal cancer cells inhibits constitutively activated protein kinase B (AKT) and cell proliferation.Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival.A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activityCan Some Marine-Derived Fungal Metabolites Become Actual Anticancer Agents?Multi-Scale Genomic, Transcriptomic and Proteomic Analysis of Colorectal Cancer Cell Lines to Identify Novel BiomarkersThe effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)Prospective noninterventional study on the use of panitumumab monotherapy in patients with recurrent or progressive colorectal cancer: the VECTIS study.Systemic treatment of patients with metachronous peritoneal carcinomatosis of colorectal origin.Mechanisms that contribute to the tendency to continue chemotherapy in patients with advanced cancer. Qualitative observations in the clinical settingAlisertib Induces Cell Cycle Arrest, Apoptosis, Autophagy and Suppresses EMT in HT29 and Caco-2 Cells.Patterns of Treatment Sequences in Chemotherapy and Targeted Biologics for Metastatic Colorectal Cancer: Findings from a Large Community-Based Cohort of Elderly Patients.Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?Targeted therapies in colorectal cancer: surgical considerations.Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15.Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients.Challenges in shared decision making in advanced cancer care: a qualitative longitudinal observational and interview studyPhospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer.FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation.Patterns of recurrence after liver transplantation for nonresectable liver metastases from colorectal cancerERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer.Real-world experience with colorectal cancer chemotherapies: patient web forum analysis.Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapyKIT Signaling Promotes Growth of Colon Xenograft Tumors in Mice and Is Up-Regulated in a Subset of Human Colon Cancers.The cytotoxic effects of regorafenib in combination with protein kinase D inhibition in human colorectal cancer cells.Current and Novel Treatment Options for Metastatic Colorectal Cancer: Emphasis on Aflibercept.
P2860
Q26740067-58F02F08-53CC-4848-881A-B8769C8F0C96Q26744056-82A8CF4C-0A06-4484-8D86-ECD0585CBBCFQ27852057-456B7100-D90C-4473-BFEC-2A11B0B0D30DQ28545198-06228D7F-BD74-4E9F-8770-CB212B81D517Q30317446-7AC4880F-415D-4869-9168-0F81BDF7B4CBQ30558513-D5C043F1-B5A8-4D6B-B161-9AFA59E17C01Q33606415-92BC619E-9205-4FFB-918B-1C4C3EE6B3B9Q33806752-C5BDB9EB-18B0-4AF6-8809-C9A711FDD63AQ33838524-B0BA183B-8D9F-415A-868C-B249EF9CD9DBQ34207776-7B1B3B59-2ABC-4C1D-96FF-361B8CCA17B0Q34635176-B0CCAF57-FF00-4430-B6F2-2F22FF4A9EADQ34658579-641AE931-9815-420D-BB98-A33290C121EBQ34894115-2884B0DF-055C-48D3-8AEF-597B2309A32DQ35026527-7240C862-B4D5-42A1-B4F7-3C563985ADFCQ35067937-E15901E7-F2B0-4B9B-98B1-0C14C86A8FB4Q35114983-CF44E54D-EFA8-40EC-9737-190F7A82A372Q35604265-BD2FBC4B-6901-4960-BBAC-A13299A0ED2DQ35790810-DCF9154E-8A1B-42CD-95E1-EC7091CC4039Q35871650-67CD47F5-B5FE-4C34-A935-D97280026B13Q35938926-9989F473-8BAD-4453-960F-A59CC8A462D2Q36232353-9D70598E-03EA-45E1-ABCA-D630D307FEF1Q36388283-1BFF4457-65F2-48E3-B9E1-94CBB075BA99Q36510951-52DED986-D85F-4D50-8BF2-39C5C4D56A64Q36512454-F7540B91-C35B-4566-81F2-1D7D01B4313DQ36761488-3E864260-AA7E-4E7C-A65D-C5ED00577CF3Q36936900-15C56DD4-FC69-4C07-8340-379AD2CDEB06Q37015697-D57B7DD3-797B-4309-8233-AA144627D0D5Q37323344-C5D6C4C7-D67B-463F-BA83-EE41F9002AC4Q37408810-4CC6A166-8467-4E78-A68A-89947C8D8E7DQ37567742-B73545B5-68E5-43A0-A700-3D42528D08ACQ37569554-41164FA1-E0F1-41E7-A1C3-B60C055ED4F5Q37580764-68163A7D-E6BF-40B9-82DE-3548CAE684A4Q37617490-869E308C-B4E5-4C42-BC7E-693612A9DB17Q38532510-D189AFB3-A92B-41FD-91BC-3AEBC9893EA5Q39305060-BB111629-7D0A-4127-AF96-84905CCC93E2Q39579889-57266F17-F8D7-4D84-845D-ABB5BC8D5631Q41891394-BD24A230-6BCD-4F18-9EA1-3B8BCA72C5DAQ42434225-DFFACE83-0234-448F-9DC2-F8D91C3F7CE0Q42775518-E4F7F04A-F488-44CF-A9C6-97EFC30ABD74
P2860
An update on the current and emerging targeted agents in metastatic colorectal cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
An update on the current and emerging targeted agents in metastatic colorectal cancer.
@en
An update on the current and emerging targeted agents in metastatic colorectal cancer.
@nl
type
label
An update on the current and emerging targeted agents in metastatic colorectal cancer.
@en
An update on the current and emerging targeted agents in metastatic colorectal cancer.
@nl
prefLabel
An update on the current and emerging targeted agents in metastatic colorectal cancer.
@en
An update on the current and emerging targeted agents in metastatic colorectal cancer.
@nl
P356
P1476
An update on the current and emerging targeted agents in metastatic colorectal cancer.
@en
P2093
Edward Chu
P356
10.2217/CRC.11.10
P407
P577
2011-07-12T00:00:00Z